Biological actions and metabolism of currently used pharmacological agents for the treatment of congestive heart failure

Current Drug Metabolism

Volumn 10, Issue 3, 2009, Pages 206-219

  Saini Chohan, Harjot K ^a   Hatch, Grant M ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

blockers; Aldosterone antagonists; Angiotensin converting enzyme inhibitors; Angiotensin receptor blockers; Digoxin; Diuretics; Vasodilators

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CANDESARTAN; CANDESARTAN HEXETIL; CAPTOPRIL; CARDIAC GLYCOSIDE; CARVEDILOL; DIGITALIS; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPLERENONE; FOSINOPRIL; FUROSEMIDE; LISINOPRIL; LOOP DIURETIC AGENT; LOSARTAN; METOPROLOL; NEBIVOLOL; PLACEBO; QUINAPRIL; RAMIPRIL; SPIRONOLACTONE; UNINDEXED DRUG; VALSARTAN; VASODILATOR AGENT;

ACUTE HEART INFARCTION; ANGIONEUROTIC EDEMA; BETA ADRENERGIC RECEPTOR BLOCKING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPETITIVE INHIBITION; CONGESTIVE HEART FAILURE; COUGHING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG ELIMINATION; DRUG ERUPTION; DRUG HYDROXYLATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TRANSFORMATION; DRY COUGH; ENANTIOMER; FIRST PASS EFFECT; FOOD; FOOD DRUG INTERACTION; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HORMONE ACTION; HUMAN; HYPERKALEMIA; HYPOKALEMIA; HYPOTENSION; KIDNEY DISEASE; KIDNEY DYSFUNCTION; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LOW DRUG DOSE; MEAL; MONOTHERAPY; MORTALITY; PROTON SODIUM EXCHANGE; RECEPTOR AFFINITY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SODIUM ABSORPTION; TASTE DISORDER; VASOCONSTRICTION; VASODILATATION;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CARDIAC GLYCOSIDES; CLINICAL TRIALS AS TOPIC; DIURETICS; HEART FAILURE; HUMANS;

EID: 65549126679     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920009787846314     Document Type: Review

References (185)

1. Francis G.S.; Cohn, J.N. Heart failure, mechanisms of cardiac and vascular dysfunction and the rationale for pharmacologic intervention. FASEB J., 1990, 4(13), 3068-3075.
2. Rosamond, W.; Flegal, K.; Furie, K.; Go, A.; Greenlund, K.; Haase, N.; Hailpern, S.M.; Ho, M.; Howard, V.; Kissela, B.; Kittner, S.; Lloyd-Jones, D.; McDermott, M.; Meigs, J.; Moy, C.; Nichol, G.; O'Donnell, C.; Roger, V.; Sorlie, P.; Steinberger, J.; Thom, T.; Wilson M.; Hong Y. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2008 update, a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation, 2008, 117(4), e25-e146.
3. Lloyd-Jones, D.M.; Larson, M.G.; Leip, E.P.; Beiser, A.; D'Agostino, R.B.; Kannel, W.B.; Murabito, J.M.; Vasan, R.S.; Benjamin, E.J.; Levy, D. Framingham Heart Study. Lifetime risk for developing congestive heart failure, the Framingham Heart Study. Circulation, 2002, 106(24), 3068-3072.
4. Burt, C.W.; Schappert, S.M. Ambulatory care visits to physician offices, hospital outpatient departments, and emergency departments, United States, 1999-2000. Vital Health Stat., 2004, 13 (157), 1-70.
5. Vitali, E.; Colombo, T.; Fratto, P.; Russo, C.; Bruschi, G.; Frigerio, M. Surgical therapy in advanced heart failure. Am. J. Cardiol., 2003, 91(9A), 88F-94F.
6. Boehmer, J.P. Device therapy for heart failure. Am. J. Cardiol., 2003, 91(6A),53D-59D.
7. Chiu, R.C. Bone-marrow stem cells as a source for cell therapy. Heart Fail. Rev., 2003, 8(3), 247-251.
8. Sethi, R.; Saini, H.K.; Elimban, V.; Dhalla, N.S. Pathophysiology and treatment of heart failure. In Pharmacotherapy of Heart Failure; Gupta, S.K.; Agrawal, S.S.; Singal, P.K.; Eds. Anamaya Publishers, New Delhi, 2005, pp.16-37.
9. Guo, X.; Saini, H.K.; Wang, J.; Gupta, S.K.; Goyal, R.K.; Dhalla, N. S. Prevention of remodeling in congestive heart failure due to myocardial infarction by blockade of the renin-angiotensin system. Expert. Rev. Cardiovasc. Ther., 2005, 3 (4), 717-732.
10. Willenbrock, R.; Philipp, S.; Mitrovic, V.; Dietz, R. Neurohumoral blockade in CHF management. J. Renin Angiotensin Aldosterone Syst., 2000, 1 (Suppl 1), 24-30.
11. Dhalla, N.S.; Afzal, N.; Beamish, R.E.; Naimark, B.; Takeda, N.; Nagano, M. Pathophysiology of cardiac dysfunction in congestive heart failure. Can. J. Cardiol., 1993, 9(10), 873-887.
12. Babick, A.P., Dhalla, N.S. Role of subcellular remodeling in cardiac dysfunction due to congestive heart failure. Med. Princ. Pract., 2007, 16(2), 81-89.
13. Packer, M. Neurohormonal interactions and adaptations in congestive heart failure. Circulation, 1988, 77(4), 721-730.
14. Tan, L.B.; Schlosshan, D.; Barker, D. Fiftieth anniversary of aldosterone, from discovery to cardiovascular therapy. Int. J. Cardiol., 2004, 96(3), 321-333.
15. Ramires, F.J.; Sun, Y.; Weber, K.T. Myocardial fibrosis associated with aldosterone or angiotensin II administration, attenuation by calcium channel blockade. J. Mol. Cell. Cardiol., 1998, 30(3), 475-483.
16. White, C.M. Pharmacologic, pharmacokinetic, and therapeutic differences among ACE inhibitors. Pharmacotherapy, 1998, 18(3), 588-599.
17. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N. Engl. J. Med., 1987, 316(23), 1429-1435.
18. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med., 1991, 325(5), 293-302.
19. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N. Engl. J. Med., 1992, 327(10), 685-691.
20. Sculpher, M.J.; Poole, L.; Cleland, J.; Drummond, M.; Armstrong, P.W.; Horowitz, J.D.; Massie, B.M.; Poole-Wilson, P.A.; Ryden, L. Low doses vs. high doses of the angiotensin converting-enzyme inhibitor lisinopril in chronic heart failure, a cost-effectiveness analysis based on the Assessment of Treatment with Lisinopril and Survival (ATLAS) study. The ATLAS Study Group. Eur. J. Heart Fail., 2000, 2(4), 447-454.
21. Erhardt, L.; MacLean, A.; Ilgenfritz, J; Gelperin, K; Blumenthal, M. Fosinopril attenuates clinical deterioration and improves exercise tolerance in patients with heart failure. Fosinopril Efficacy/Safety Trial (FEST) Study Group. Eur. Heart J., 1995, 16(12), 1892-1899.
22. Guidelines for the evaluation and management of heart failure. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure). Circulation, 1995, 92(9), 2764-2784.
23. Cohn, J.N. The management of chronic heart failure. N. Engl. J. Med., 1996, 335(7), 490-498.
24. Zannad, F.; Chati, Z.; Guest, M.; Plat, F. Differential effects of fosinopril and enalapril in patients with mild to moderate chronic heart failure. Fosinopril in heart failure study investigators. Am. Heart J., 1998, 136(4 Pt 1), 672-680.
25. Bach, R.; Zardini, P. Long-acting angiotensin-converting enzyme inhibition, once-daily lisinopril versus twice-daily captopril in mild-to-moderate heart failure. Am. J. Cardiol., 1992, 70(10), 70C-77C.
26. Zannad, F.; van den Broek, S.A.; Bory, M. Comparison of treatment with lisinopril versus enalapril for congestive heart failure. Am. J. Cardiol., 1992, 70(10), 78C-83C.
27. Garg, R.; Yusuf, S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative group on ACE inhibitor trials. JAMA, 1995, 273(18), 1450-1456.
28. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet, 1993, 342(8875), 821-828.
29. Krum, H.; Gilbert, R.E. Demographics and concomitant disorders in heart failure. Lancet, 2003, 362(9378), 147-158.
30. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction, systematic overview of individual data from 100,000 patients in randomized trials. Circulation, 1998, 97(22), 2202-2212.
31. White, C.M. Angiotensin-converting-enzyme inhibition in heart failure or after myocardial infarction. Am. J. Health Syst. Pharm., 2000, 57 (Suppl 1), S18-S25.
32. Kelly, J.G.; O'Malley, K. Clinical pharmacokinetics of the newer ACE inhibitors. A review. Clin. Pharmacokinet., 1990, 19(3), 177-196.
33. Vertes, V.; Haynie, R. Comparative pharmacokinetics of captopril, enalapril, and quinapril. Am. J. Cardiol., 1992, 69(10), 8C-16C.
34. Kubo, S. H; Cody, R. J. Clinical pharmacokinetics of the angiotensin converting enzyme inhibitors. A review. Clin. Pharmacokinet., 1985, 10(5), 377-391.
35. Kirsten, R.; Nelson, K.; Kirsten, D.; Heintz, B. Clinical pharmacokinetics of vasodilators. Part I. Clin. Pharmacokinet., 1998, 34(6), 457-482.
36. Ohnishi, A.; Tsuboi, Y.; Ishizaki, T.; Kubota, K.; Ohno, T.; Yoshida, H.; Kanezaki, A.; Tanaka, T. Kinetics and dynamics of enalapril in patients with liver cirrhosis. Clin. Pharmacol. Ther., 1989, 45(6), 657-665.
37. Baba, T.; Murabayashi, S.; Tomiyama, T.; Takebe, K. The pharmacokinetics of enalapril in patients with compensated liver cirrhosis. Br. J. Clin. Pharmacol., 1990, 29(6), 766-769.
38. White, W.B.; Fox, A.A.; Stimpel, M. Long-term efficacy and safety of moexipril in the treatment of hypertension. J. Hum. Hypertens., 1994, 8(12), 917-921.
39. Grass, P.; Gerbeau, C.; Kutz, K. Spirapril, pharmacokinetic properties and drug interactions. Blood Press. Suppl., 1994, 2, 7-13.
40. Puchler, K.; Sierakowski, B.; Roots, I. Single dose and steady state pharmacokinetics of temocapril and temocaprilat in young and elderly hypertensive patients. Br. J. Clin. Pharmacol., 1998, 46(4), 363-367.
41. Harder, S.; Thurmann, P.A.; Ungethüm, W. Single dose and steady state pharmacokinetics and pharmacodynamics of the ACE-inhibitor imidapril in hypertensive patients. Br. J. Clin. Pharmacol., 1998, 45(4), 377-380.
42. Greenbaum, R.; Zucchelli, P.; Caspi, A.; Nouriel, H.; Paz, R.; Sclarovsky, S.; O'Grady, P.; Yee, K.F.; Liao, W.C.; Mangold, B. Comparison of the pharmacokinetics of fosinoprilat with enalaprilat and lisinopril in patients with congestive heart failure and chronic renal insufficiency. Br. J. Clin. Pharmacol., 2000, 49(1), 23-31.
43. Singhvi, S.M.; Duchin, K.L.; Morrison, R.A.; Willard, D.A.; Everett, D.W.; Frantz, M. Disposition of fosinopril sodium in healthy subjects. Br. J. Clin. Pharmacol., 1988, 25(1), 9-15.
44. Hoyer, J.; Schulte, K.L.; Lenz, T. Clinical pharmacokinetics of angiotensin converting enzyme (ACE) inhibitors in renal failure. Clin. Pharmacokinet., 1993, 24(3), 230-254.
45. Hui, K.K.; Duchin, K.L.; Kripalani, K.J.; Chan, D.; Kramer, P.K.; Yanagawa, N. Pharmacokinetics of fosinopril in patients with various degrees of renal function. Clin. Pharmacol. Ther., 1991, 49(4), 457-467.
46. Pitt, B. Importance of angiotensin-converting enzyme inhibitors in myocardial infarction and congestive heart failure, implications for clinical practice. Cardiology, 1995, 86 (Suppl 1), 41-45.
47. Israili, Z.H.; Hall, W.D. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann. Intern. Med., 1992, 117(3), 234-242.
48. Finley, C.J., Silverman, M.A., Nunez, A.E. Angiotensin-converting enzyme inhibitor-induced angioedema, still unrecognized. Am. J. Emerg. Med., 1992, 10(6), 550-552.
49. Brown, N.J., Ray, W.A., Snowden, M., Griffin, M.R. Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Clin. Pharmacol. Ther., 1996, 60(1),8-13.
50. Slater, E.E., Merrill, D.D., Guess, H.A., Roylance, P.J., Cooper, W. D., Inman, W.H., Ewan, P.W. Clinical profile of angioedema associated with angiotensin converting-enzyme inhibition. JAMA., 1988, 260(7), 967-970.
51. Erdmann, E. The management of heart failure - an overview. Basic Res. Cardiol., 2000, 95 (Suppl 1), I3-I7.
52. McMurray, J.J. Angiotensin receptor blockers for chronic heart failure and acute myocardial infarction. Heart, 2001, 86(1), 97-103.
53. Tarazi, R.C.; Fouad, F.M.; Ceimo, J.K.; Bravo, E.L. Renin, aldosterone and cardiac decompensation, studies with an oral converting enzyme inhibitor in heart failure. Am. J. Cardiol., 1979, 44(5), 1013-1018.
54. MacFadyen, R.J.; Lee, A.F.; Morton, J.J.; Pringle, S.D.; Struthers, A. D. How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Heart, 1999, 82(1), 57-61.
55. Urata, H.; Healy, B.; Stewart, R.W.; Bumpus, F.M.; Husain, A. Angiotensin II-forming pathways in normal and failing human hearts. Circ. Res., 1990, 66(4), 883-890.
56. Unger, T. Significance of angiotensin type 1 receptor blockade, why are angiotensin II receptor blockers different? Am. J. Cardiol., 1999, 84(10A), 9S-15S.
57. Csajka, C.; Buclin, T.; Brunner, H.R.; Biollaz, J. Pharmacokinetic-pharmacodynamic profile of angiotensin II receptor antagonists. Clin. Pharmacokinet., 1997, 32(1), 1-29.
58. Pitt, B.; Segal, R.; Martinez, F.A.; Meurers, G.; Cowley, A.J.; Thomas, I.; Deedwania, P.C.; Ney, D.E.; Snavely, D.B.; Chang, P. I. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet, 1997, 349(9054), 747-752.
59. Pitt, B.; Poole-Wilson, P.A.; Segal, R.; Martinez, F.A.; Dickstein, K.; Camm, A.J.; Konstam, M.A.; Riegger, G.; Klinger, G.H.; Neaton, J.; Sharma, D.; Thiyagarajan, B. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure, randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet, 2000, 355(9215), 1582-1587.
60. Cohn, J.N.; Tognoni, G. Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N. Engl. J. Med., 2001, 345(23), 1667-1675.
61. Yusuf, S.; Pfeffer, M.A.; Swedberg, K.; Granger, C.B.; Held, P.; McMurray, J.J.; Michelson, E.L.; Olofsson, B.; Ostergren, J. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction, the CHARM-Preserved Trial. Lancet, 2003, 362(9386), 777-781.
62. Granger, C.B.; McMurray, J.J.; Yusuf, S.; Held, P.; Michelson, E.L.; Olofsson, B.; Ostergren, J.; Pfeffer, M.A.; Swedberg, K. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors, the CHARM-Alternative trial. Lancet, 2003, 362(9386), 772-776.
63. McMurray, J.J.; Ostergren, J.; Swedberg, K.; Granger, C.B.; Held, P.; Michelson, E.L.; Olofsson, B.; Yusuf, S., Pfeffer, M. A. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors, the CHARM-Added trial. Lancet, 2003, 362(9386), 767-771.
64. Pitt, B. Clinical trials of angiotensin receptor blockers in heart failure, what do we know and what will we learn? Am. J. Hypertens., 2002, 15(1 Pt 2), 22S-27S.
65. Dickstein, K.; Kjekshus, J. OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction, the OPTIMAAL randomised trial. Optimal trial in myocardial infarction with angiotensin ii antagonist losartan. Lancet, 2002, 360(9335), 752-760.
66. Pfeffer, M.A.; McMurray, J.J.; Velazquez, E.J.; Rouleau, J.L.; Køber, L.; Maggioni, A.P.; Solomon, S.D.; Swedberg, K.; Van de Werf, F.; White, H.; Leimberger, J.D.; Henis, M.; Edwards, S.; Zelenkofske, S.; Sellers, M.A.; Califf, R.M. Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N. Engl. J. Med., 2003, 349(20), 1893-1906.
67. McKelvie, R.S.; Yusuf, S.; Pericak, D.; Avezum, A.; Burns, R.J.; Probstfield, J.; Tsuyuki, R.T.; White, M.; Rouleau, J.; Latini, R.; Maggioni, A.; Young, J.; Pogue, J. Comparison of candesartan, enalapril, and their combination in congestive heart failure, randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation, 1999, 100(10), 1056-1064.
68. Wong, P.C.; Price, W. A. Jr.; Chiu, A.T.; Duncia, J.V.; Carini, D.J.; Wexler, R.R.; Johnson, A.L.; Timmermans, P. B. Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174, an active metabolite of DuP 753, an orally active antihypertensive agent. J. Pharmacol. Exp. Ther., 1990, 255(1), 211-217.
69. Lo, M.W.; Goldberg, M.R.; McCrea, J.B.; Lu, H.; Furtek, C.I.; Bjornsson, T.D. Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin. Pharmacol. Ther., 1995, 58(6), 641-649.
70. Yasar, U.; Forslund-Bergengren, C.; Tybring, G.; Dorado, P.; Llerena, A.; Sjöqvist, F.; Eliasson, E.; Dahl, M.L. Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clin. Pharmacol. Ther., 2002, 71(1), 89-98.
71. Stearns, R.A.; Chakravarty, P.K.; Chen, R.; Chiu, S.H. Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members. Drug Metab. Dispos., 1995, 23(2), 207-215.
72. Sica, D.A.; Lo, M.W.; Shaw, W.C.; Keane, W.F.; Gehr, T.W.; Halstenson, C.E.; Lipschutz, K.; Furtek, C.I.; Ritter, M.A.; Shahinfar, S. The pharmacokinetics of losartan in renal insufficiency. J. Hypertens. Suppl., 1995, 13(1), S49-S52.
73. Song, J.C.; White, C.M. Pharmacologic, pharmacokinetic, and therapeutic differences among angiotensin II receptor antagonists. Pharmacotherapy, 2000, 20(2), 130-139.
74. Noda, M.; Shibouta, Y.; Inada, Y.; Ojima, M.; Wada, T.; Sanada, T.; Kubo, K.; Kohara, Y.; Naka, T.; Nishikawa, K. Inhibition of rabbit aortic angiotensin II (AII) receptor by CV-11974, a new nonpeptide AII antagonist. Biochem. Pharmacol., 1993, 46(2), 311-318.
75. Israili, Z.H. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J. Hum. Hypertens., 2000, 14 (Suppl 1), S73-S86.
76. Oparil, S. Newly emerging pharmacologic differences in angiotensin II receptor blockers. Am. J. Hypertens., 2000, 13(1 Pt 2), 18S-24S.
77. Weber, K.T. Aldosterone in congestive heart failure. N. Engl. J. Med., 2001, 345(23), 1689-1697.
78. Struthers, A.D. Why does spironolactone improve mortality over and above an ACE inhibitor in chronic heart failure? Br. J. Clin. Pharmacol., 1999, 47(5), 479-482.
79. Jorde, U.P.; Vittorio, T.; Katz, S.D.; Colombo, P.C.; Latif, F.; Le Jemtel, T. H. Elevated plasma aldosterone levels despite complete inhibition of the vascular angiotensin-converting enzyme in chronic heart failure. Circulation, 2002, 106(9), 1055-1057.
80. Staessen, J., Lijnen, P.; Fagard, R.; Verschueren, L.J.; Amery, A. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J. Endocrinol., 1981, 91(3), 457-465.
81. Borghi, C.; Boschi, S.; Ambrosioni, E.; Melandri, G.; Branzi, A.; Magnani, B. Evidence of a partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors. J. Clin. Pharmacol., 1993, 33(1), 40-45.
82. Tait, J.F.; Little, B.; Tait, S.A.; Flood, C.; Bougas, J. Splanchnic extraction and clearance of aldosterone in subjects with minimal and marked cardiac dysfunction. J. Clin. Endocrinol. Metab., 1965, 25, 219-228.
83. Wimett, L.; Laustsen, G. Inspra improves survival for CHF patients. Nurse Pract., 2004, 29(7), 56-59.
84. Pitt, B.; Zannad, F.; Remme, W.J.; Cody, R.; Castaigne, A.; Perez, A.; Palensky, J.; Wittes, J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med., 1999, 341(10), 709-717.
85. Pitt, B.; Remme, W.; Zannad, F.; Neaton, J.; Martinez, F.; Roniker, B.; Bittman, R.; Hurley, S.; Kleiman, J.; Gatlin, M. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med., 2003, 348(14), 1309-1321.
86. Zannad, F.; Alla, F.; Dousset, B.; Perez, A.; Pitt, B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure, insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation, 2000, 102(22), 2700-2706.
87. Menard, J. The 45-year story of the development of an antialdosterone more specific than spironolactone. Mol. Cell. Endocrinol., 2004, 217(1-2), 45-52.
88. Sica, D. A. Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Heart Fail. Rev., 2005, 10(1), 23-29.
89. Overdiek, H.W.; Merkus, F. W. The metabolism and biopharmaceutics of spironolactone in man. Rev. Drug Metab. Drug Interact., 1987, 5(4), 273-302.
90. Gardiner, P.; Schrode, K.; Quinlan, D.; Martin, B.K.; Boreham, D.R.; Rogers, M.S.; Stubbs, K.; Smith, M.; Karim, A. Spironolactone metabolism, steady-state serum levels of the sulfur-containing metabolites. J. Clin. Pharmacol., 1989, 29(4), 342-347.
91. Overdiek, H.W., Merkus, F.W. Influence of food on the bioavailability of spironolactone. Clin. Pharmacol. Ther., 1986, 40(5), 531-536.
92. Melander, A. Influence of food on the bioavailability of drugs. Clin. Pharmacokinet. 1978, 3(5), 337-351.
93. Cook, C.S.; Berry, L.M.; Kim, D.H.; Burton, E.G.; Hribar, J.D.; Zhang, L. Involvement of CYP3A in the metabolism of eplerenone in humans and dogs, differential metabolism by CYP3A4 and CYP3A5. Drug Metab. Dispos., 2002, 30(12), 1344-1351.
94. Ravis, W.R.; Reid, S.; Sica, D.A.; Tolbert, D. S. Pharmacokinetics of eplerenone after single and multiple dosing in subjects with and without renal impairment. J. Clin. Pharmacol., 2005, 45(7), 810-821.
95. Cook, C.S.; Berry, L.M.; Bible, R.H.; Hribar, J.D.; Hajdu, E.; Liu, N. W. Pharmacokinetics and metabolism of [14C]eplerenone after oral administration to humans. Drug Metab. Dispos., 2003, 31(11), 1448-1455.
96. Sica, D.A.; Gehr, T.W.; Yancy, C. Hyperkalemia, congestive heart failure, and aldosterone receptor antagonism. Congest. Heart Fail., 2003, 9(4), 224-229.
97. Kostis, J.B.; Shelton, B.; Gosselin, G.; Goulet, C.; Hood, W.B. Jr.; Kohn, R.M.; Kubo, S.H.; Schron, E.; Weiss, M.B.; Willis, P. W. 3rd.; Young, J.B.; Probstfield, J. Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction (SOLVD). SOLVD Investigators. Am. Heart J., 1996, 131(2), 350-355.
98. Hiranyachattada, S.; Saetew, S.; Harris, P.J. Acute effects of candesartan on rat renal haemodynamics and proximal tubular reabsorption. Clin. Exp. Pharmacol. Physiol., 2005, 32(9), 714-720.
99. Wang, X.; Dhalla, N.S. Modification of beta-adrenoceptor signal transduction pathway by genetic manipulation and heart failure. Mol. Cell. Biochem., 2000, 214(1-2), 131-155.
100. Choi, D.J.; Rockman, H.A. Beta-adrenergic receptor desensitization in cardiac hypertrophy and heart failure. Cell. Biochem. Biophys., 1999, 31(3), 321-329.
101. Dhalla, N.S.; Wang, X.; Sethi, R.; Das, P.K.; Beamish, R.E. Beta-adrenergic linked signal transduction in failing hearts. Heart Fail. Rev., 1997, 2, 55-65.
102. Epstein, S.E.; Braunwald, E. The effect of beta adrenergic blockade on patterns of urinary sodium excretion. Studies in normal subjects and in patients with heart disease. Ann. Intern. Med., 1966, 65(1), 20-27.
103. Bristow, M.; Port, J.D. Beta-adrenergic blockade in chronic heart failure. Scand. Cardiovasc. J. Suppl., 1998, 47, 45-55.
104. Sabbah, H.N. Biologic rationale for the use of beta-blockers in the treatment of heart failure. Heart Fail. Rev., 2004, 9(2), 91-97.
105. Krum, H. Beta-blockers in heart failure. The 'new wave' of clinical trials. Drugs, 1999, 58(2), 203-210.
106. Patterson, J.H.; Rodgers, J.E. Expanding role of beta-blockade in the management of chronic heart failure. Pharmacotherapy, 2003, 23(4), 451-459.
107. Hjalmarson, A.; Goldstein, S.; Fagerberg, B; Wedel, H; Waagstein, F.; (Sweden), Kjekshus, J.; Wikstrand, J.; Westergren, G.; Thimell, M. Effect of metoprolol CR/XL in chronic heart failure, Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) Lancet, 1999, 353(9169), 2001-2007.
108. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II), a randomised trial. Lancet, 1999, 353(9146), 9-13.
109. Packer, M.; Bristow, M.R.; Cohn, J.N.; Colucci, W.S.; Fowler, M.B.; Gilbert, E.M.; Shusterman, N.H. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N. Engl. J. Med., 1996, 334(21), 1349-1355.
110. Eichhorn, E.J.; Bristow, M.R. The Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Curr. Control Trials Cardiovasc. Med., 2001, 2(1), 20-23.
111. Cleland, J.G.; Bristow, M.R.; Erdmann, E.; Remme, W.J.; Swedberg, K.; Waagstein, F. Beta-blocking agents in heart failure. Should they be used and how? Eur. Heart J., 1996, 17(11), 1629-1639.
112. Strauer, B.E. Beta-blocking agents in heart failure, modern concepts and overview. J Cardiovasc. Pharmacol., 1990, 16 (Suppl 5), S129-S132.
113. Blumenfeld, J.D.; Sealey, J.E.; Mann, S.J.; Bragat, A.; Marion, R.; Pecker, M.S.; Sotelo, J.; August, P.; Pickering, T.G.; Laragh, J. H. Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects. Am. J. Hypertens., 1999, 12(5), 451-459.
114. Holmer, S.R.; Hengstenberg, C.; Mayer, B.; Engel, S.; Lowel, H.; Riegger, G.A.; Schunkert, H. Marked suppression of renin levels by beta-receptor blocker in patients treated with standard heart failure therapy, a potential mechanism of benefit from beta-blockade. J. Intern. Med., 2001, 249(2),167-172.
115. Bristow, M. Carvedilol tratment of chronic heart failure, a new era. Heart, 1998, 79 (Suppl 2), S31-S34.
116. Poole-Wilson, P.A.; Swedberg, K.; Cleland, J.G.; Di Lenarda, A.; Hanrath, P.; Komajda, M.; Lubsen, J.; Lutiger, B.; Metra, M.; Remme, W.J.; Torp-Pedersen, C.; Scherhag, A.; Skene, A. Carvedilol Or Metoprolol European Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET), randomised controlled trial. Lancet, 2003, 362(9377), 7-13.
117. Weber, M.A. The role of the new beta-blockers in treating cardiovascular disease. Am. J. Hypertens., 2005, 18(12 Pt 2), 169S-176S.
118. Flather, M.D.; Shibata, M.C.; Coats, A.J.; Van Veldhuisen, D.J.; Parkhomenko, A.; Borbola, J.; Cohen-Solal, A.; Dumitrascu, D.; Ferrari, R.; Lechat, P.; Soler-Soler, J.; Tavazzi, L.; Spinarova, L.; Toman, J.; Bohm, M; Anker, S.D.; Thompson, S.G.; Poole-Wilson, P. A. SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur. Heart J., 2005, 26(3), 215-225.
119. Domanski, M.J.; Krause-Steinrauf, H.; Massie, B.M.; Deedwania, P.; Follmann, D.; Kovar, D.; Murray, D.; Oren, R.; Rosenberg, Y.; Young, J.; Zile, M.; Eichhorn, E. BEST Investigators. A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure, BEST, CIBIS-II, MERIT-HF, and COPERNICUS. J. Card. Fail., 2003, 9(5), 354-363.
120. The Xamoterol in Severe Heart Failure Study Group. Xamoterol in severe heart failure. Lancet, 1990, 336(8706), 1-6.
121. Tang, W.H.; Francis, G. S. Polypharmacy of heart failure. Creating a rational pharmacotherapeutic protocol. Cardiol. Clin., 2001, 19(4), 583-596, viii.
122. Haeusler, G.; Schliep, H.J.; Schelling, P.; Becker, K.H.; Klockow, M.; Minck, K.O.; Enenkel, H.J.; Schulze, E; Bergmann, R; Schmitges, C. J. High beta 1-selectivity and favourable pharmacokinetics as the outstanding properties of bisoprolol. J. Cardiovasc. Pharmacol., 1986, 8 (Suppl 11), S2-S15.
123. Horikiri, Y.; Suzuki, T.; Mizobe, M. Pharmacokinetics and metabolism of bisoprolol enantiomers in humans. J. Pharm. Sci., 1998, 87(3), 289-294.
124. Horikiri, Y.; Suzuki, T.; Mizobe, M. Stereoselective metabolism of bisoprolol enantiomers in dogs and humans. Life. Sci., 1998, 63(13), 1097-1108.
125. Talbert, R. L. Pharmacokinetics and pharmacodynamics of beta blockers in heart failure. Heart Fail. Rev., 2004, 9(2), 131-137.
126. Li, F.; Cooper, S.F.; Cote, M. Determination of the enantiomers of metoprolol and its major acidic metabolite in human urine by highperformance liquid chromatography with fluorescence detection. J. Chromatogr. B. Biomed. Appl., 1995, 668(1), 67-75.
127. Kirchheiner, J.; Heesch, C.; Bauer, S.; Meisel, C.; Seringer, A.; Goldammer, M.; Tzvetkov, M.; Meineke, I.; Roots, I.; Brockmoller, J. Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics. Clin. Pharmacol. Ther., 2004, 76(4), 302-312.
128. Seeringer, A.; Brockmoller, J.; Bauer, S.; Kirchheiner, J. Enantiospecific pharmacokinetics of metoprolol in CYP2D6 ultra-rapid metabolizers and correlation with exercise-induced heart rate. Eur. J. Clin. Pharmacol., 2008, 64(9), 883-888.
129. Wuttke, H.; Rau, T.; Heide, R.; Bergmann, K.; Bohm, M.; Weil, J.; Werner, D.; Eschenhagen, T. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprololassociated adverse effects. Clin. Pharmacol. Ther., 2002, 72(4), 429-437.
130. Stoschitzky, K.; Koshucharova, G.; Lercher, P.; Maier, R.; Sakotnik, A.; Klein, W.; Liebmann, P.M.; Lindner, W. Stereoselective effects of (R)- and (S)-carvedilol in humans. Chirality, 2001, 13(7), 342-346.
131. Tenero, D.; Boike, S.; Boyle, D.; Ilson, B.; Fesniak, H.F.; Brozena, S.; Jorkasky, D. Steady-state pharmacokinetics of carvedilol and its enantiomers in patients with congestive heart failure. J. Clin. Pharmacol., 2000, 40(8), 844-853.
132. Neugebauer, G.; Akpan, W.; Kaufmann, B.; Reiff, K. Stereoselective disposition of carvedilol in man after intravenous and oral administration of the racemic compound. Eur. J. Clin. Pharmacol., 1990, 38 (Suppl 2), S108-S111.
133. Zhou, H.H.; Wood, A. J. Stereoselective disposition of carvedilol is determined by CYP2D6. Clin. Pharmacol. Ther., 1995, 57(5), 518-524.
134. Sica, D. A. Sodium and water retention in heart failure and diuretic therapy, basic mechanisms. Cleve. Clin. J. Med., 2006, 73 (Suppl 2),S2-S7; discussion S30-S33.
135. Abraham, W.T.; Schrier, R. W. Body fluid volume regulation in health and disease. Adv. Intern. Med., 1994, 39, 23-47.
136. Taylor, S. H. Diuretic therapy in congestive heart failure. Cardiol. Rev., 2000, 8(2), 104-114.
137. Reyes, A.J. Diuretics in the treatment of patients who present congestive heart failure and hypertension. J. Hum. Hypertens., 2002, 16 (Suppl 1),S104-13.
138. Moser, M. Diuretics in the prevention and treatment of congestive heart failure. Cardiovasc. Drugs Ther., 1997, 11 (Suppl 1), 273-277.
139. Hunt, S.A. American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult, a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J. Am. Coll. Cardiol., 2005, 46(6), e1-e82.
140. Swedberg, K.; Cleland, J.; Dargie, H.; Drexler, H.; Follath, F.; Komajda, M.; Tavazzi, L.; Smiseth, O.A.; Gavazzi, A.; Haverich, A.; Hoes, A.; Jaarsma, T.; Korewicki, J.; Levy, S; Linde, C; Lopez-Sendon, J.L.; Nieminen, M.S.; Pierard, L.; Remme, W. J. Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure, executive summary (update 2005), The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur. Heart J., 2005, 26(11), 1115-1140.
141. Brater, D.C. Pharmacology of diuretics. Am. J. Med. Sci., 2000, 319(1), 38-50.
142. Lant, A. Diuretics. Clinical pharmacology and therapeutic use (Part I). Drugs, 1985, 29(1), 57-87.
143. Brater, D.C. Diuretic therapy in congestive heart failure. Congest. Heart Fail., 2000, 6(4), 197-201.
144. Chennavasin, P.; Seiwell, R.; Brater, D.C.; Liang, W. M. Pharmacodynamic analysis of the furosemide-probenecid interaction in man. Kidney Int., 1979, 16(2), 187-195.
145. De Bruyne, L.K. Mechanisms and management of diuretic resistance in congestive heart failure. Postgrad. Med. J., 2003, 79(931), 268-271.
146. Ellison, D.H. Diuretic resistance, physiology and therapeutics. Semin. Nephrol., 1999, 19(6), 581-597.
147. Wang, D.J.; Gottlieb, S. S. Diuretics, still the mainstay of treatment. Crit. Care Med., 2008, 36(1 Suppl), S89-S94.
148. Kaissling, B.; Stanton, B. A. Adaptation of distal tubule and collecting duct to increased sodium delivery. I. Ultrastructure. Am. J. Physiol. Renal Physiol., 1988, 255(6 Pt 2), F1256-F1268.
149. + transport. Am. J. Physiol. Renal Physiol., 1988, 255(6 Pt 2), F1269-F1275.
150. Dormans, T.P.; Gerlag, P.G.; Russel, F.G.; Smits, P. Combination diuretic therapy in severe congestive heart failure. Drugs, 1998, 55(2), 165-172.
151. Ward, A.; Heel, R.C. Bumetanide. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use. Drugs, 1984, 28(5), 426-464.
152. Vree, T.B.; van der Ven, A.J. Clinical consequences of the biphasic elimination kinetics for the diuretic effect of furosemide and its acyl glucuronide in humans. J. Pharm. Pharmacol., 1999, 51(3), 239-248.
153. Lesne, M. Comparison of the pharmacokinetics and pharmacodynamics of torasemide and furosemide in healthy volunteers. Arzneimittelforschung, 1988, 38(1A), 160-163.
154. Neugebauer, G; Besenfelder, E.; von Mollendorff, E. Pharmacokinetics and metabolism of torasemide in man. Arzneimittelforschung, 1988, 38(1A), 164-166.
155. Knauf, H.; Mutschler, E. Clinical pharmacokinetics and pharmacodynamics of torasemide. Clin. Pharmacokinet., 1998, 34(1), 1-24.
156. Vormfelde, S.V.; Engelhardt, S.; Zirk, A.; Meineke, I.; Tuchen, F.; Kirchheiner, J.; Brockmoller, J. CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide. Clin. Pharmacol. Ther., 2004, 76(6), 557-566.
157. Vormfelde, S.V.; Schirmer, M.; Toliat, M.R.; Meineke, I.; Kirchheiner, J.; Nurnberg, P.; Brockmoller, J. Genetic variation at the CYP2C locus and its association with torsemide biotransformation. Pharmacogenom. J., 2007, 7(3), 200-211.
158. Heller, M. Cardiac glycosides. New/old ideas about old drugs. Biochem. Pharmacol., 1990, 40(5), 919-925.
159. Campbell, T.J.; MacDonald, P. S. Digoxin in heart failure and cardiac arrhythmias. Med. J. Aust., 2003, 179(2), 98-102.
160. Smith, T. W. The basic mechanism of inotropic action of digitalis glycosides. J. Pharmacol., 1984, 15 (Suppl 1), 35-51.
161. Packer, M. The development of positive inotropic agents for chronic heart failure, how have we gone astray? J. Am. Coll. Cardiol., 1993, 4 (Suppl A), 119A-126A.
162. Kjeldsen, K.; Norgaard, A.; Gheorghiade, M. Myocardial Na,KATPase, the molecular basis for the hemodynamic effect of digoxin therapy in congestive heart failure. Cardiovasc. Res., 2002, 55(4), 710-713.
163. Eichhorn, E.J.; Gheorghiade, M. Digoxin. Prog. Cardiovasc. Dis., 2002, 44(4), 251-266.
164. Khand, A.U.; Rankin, A.C.; Martin, W.; Taylor, J.; Gemmell, I.; Cleland, J. G. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? J. Am. Coll. Cardiol., 2003, 42(11), 1944-1951.
165. Uretsky, B.F.; Young, J.B.; Shahidi, F.E.; Yellen, L.G.; Harrison, M.C.; Jolly, M.K. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure, results of the PROVED trial. PROVED Investigative Group. J. Am. Coll. Cardiol., 1993, 22(4), 955-962.
166. Packer, M.; Gheorghiade, M.; Young, J.B.; Costantini, P.J.; Adams, K.F.; Cody, R.J.; Smith, L.K.; Van Voorhees, L.; Gourley, L.A.; Jolly, M.K. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. N. Engl. J. Med., 1993, 329(1), 1-7.
167. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N. Engl. J. Med., 1997, 336 (8), 525-533.
168. Kelly, R.A.; Smith, T. W. Recognition and management of digitalis toxicity. Am. J. Cardiol., 1992, 69(18), 108G-118G; disc. 118G-119G.
169. Dec, G.W. Digoxin remains useful in the management of chronic heart failure. Med. Clin. North Am., 2003, 87(2), 317-337.
170. Rathore, S.S.; Wang, Y.; Krumholz, H. M. Sex-based differences in the effect of digoxin for the treatment of heart failure. N. Engl. J. Med., 2002, 347(18), 1403-1411.
171. Rahimtoola, S. H. Digitalis therapy for patients in clinical heart failure. Circulation, 2004, 109(24), 2942-2946.
172. Hauptman, P.J.; Kelly, R. A. Digitalis. Circulation, 1999, 99(9), 1265-1270.
173. Young, J.B.; Gheorghiade, M.; Uretsky, B.F.; Patterson, J.H.; Adams, K. F. Jr. Superiority of "triple" drug therapy in heart failure, insights from the PROVED and RADIANCE trials. Prospective Randomized Study of Ventricular Function and Efficacy of Digoxin. Randomized Assessment of Digoxin and Inhibitors of Angiotensin- Converting Enzyme. J. Am. Coll. Cardiol., 1998, 32, 686-692.
174. Dhaliwal A.S.; Bredikis, A.; Habib, G.; Carabello, B.A.; Ramasubbu, K.; Bozkurt, B. Digoxin and clinical outcomes in systolic heart failure patients on contemporary background heart failure therapy. Am. J. Cardiol., 2008, 102(10), 1356-1360.
175. Gault, M.H.; Longerich, L.L.; Loo, J.C.; Ko, P.T.; Fine, A.; Vasdev, S.C.; Dawe, M. A. Digoxin biotransformation. Clin. Pharmacol. Ther., 1984, 35 (1), 74-82.
176. Lindenbaum, J.; Rund, D.G.; Butler, V.P. Jr.; Tse-Eng, D.; Saha, J. R. Inactivation of digoxin by the gut flora, reversal by antibiotic therapy. N. Engl. J. Med., 1981, 305(14), 789-794.
177. Verschraagen, M., Koks, C.H., Schellens, J.H., Beijnen, J.H.P-glycoprotein system as a determinant of drug interactions, the case of digoxin-verapamil. Pharmacol. Res., 1999, 40(4), 301-306.
178. Nademanee, K., Kannan, R., Hendrickson, J., Ookhtens, M., Kay, I., Singh, B. N. Amiodarone-digoxin interaction, clinical significance, time course of development, potential pharmacokinetic mechanisms and therapeutic implications. J. Am. Coll. Cardiol., 1984, 4(1), 111-116.
179. Cohn, J.N.; Archibald, D.G.; Ziesche, S.; Franciosa, J.A.; Harston, W.E.; Tristani, F.E.; Dunkman, W.B.; Jacobs, W.; Francis, G.S.; Flohr, K. H. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N. Engl. J. Med., 1986, 314(24), 1547-1552.
180. Cohn, J.N.; Johnson, G.; Ziesche, S.; Cobb, F.; Francis, G.; Tristani, F.; Smith, R.; Dunkman, W.B.; Loeb, H.; Wong, M. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N. Engl. J. Med., 1991, 325(5), 303-310.
181. Thackray, S.; Coletta, A.; Jones, P.; Dunn, A.; Clark, A.L.; Cleland, J.G. Clinical trials update, Highlights of the Scientific Sessions of Heart Failure 2001, a meeting of the Working Group on Heart Failure of the European Society of Cardiology. CONTAKCD, CHRISTMAS, OPTIME-CHF. Eur. J. Heart Fail., 2001, 3(4), 491-494.
182. Antoniades, C.; Tousoulis, D.; Koumallos, N.; Marinou, K.; Stefanadis, C. Levosimendan, beyond its simple inotropic effect in heart failure. Pharmacol. Ther., 2007, 114(2), 184-197.
183. Perrone, S.V.; Kaplinsky, E.J. Calcium sensitizer agents, a new class of inotropic agents in the treatment of decompensated heart failure. Int. J. Cardiol., 2005, 103(3), 248-255.
184. Remme, W.J. Pharmacological modulation of cardiovascular remodeling, a guide to heart failure therapy. Cardiovasc. Drugs Ther., 2003, 17(4), 349-360.
185. Weber, M.A. Vasopeptidase inhibitors. Lancet, 2001, 358(9292), 1525-1532.